Evofem Biosciences Inc. [NASDAQ: EVFM] price plunged by -1.42 percent to reach at -$0.02. The company report on May 21, 2021 that Evofem Biosciences Announces Closing of $50 Million Public Offering.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock. In addition, Evofem granted the underwriter a 30-day option to purchase up to an additional 7.5 million shares of its common stock and/or accompanying warrants to purchase an aggregate of up to 7.5 million shares of its common stock, which the underwriter has partially exercised for warrants to purchase an aggregate of up to 7.5 million shares of common stock. At closing, Evofem received net proceeds from the offering of approximately $46.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. All of the securities in the offering were sold by Evofem.
Evofem intends to use the net proceeds from this offering for the continuation of full commercialization activities related to Phexxi® (lactic acid, citric acid and potassium bitartrate), including continued direct-to-consumer advertising activities across television, streaming and digital channels; the continuation of its ongoing EVOGUARD Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and related development activities; and general corporate purposes and other capital expenditures.
A sum of 14255318 shares traded at recent session while its average daily volume was at 6.94M shares. Evofem Biosciences Inc. shares reached a high of $0.8383 and dropped to a low of $0.80 until finishing in the latest session at $0.82.
Guru’s Opinion on Evofem Biosciences Inc. [EVFM]:
Stifel have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on August 20, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $11, while Piper Sandler analysts kept a Overweight rating on EVFM stock.
The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.11, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 54.26.
EVFM Stock Performance Analysis:
Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -35.56. With this latest performance, EVFM shares dropped by -44.64% in over the last four-week period, additionally sinking by -64.60% over the last 6 months – not to mention a drop of -83.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 21.70, with the RSI for the last a single of trading hit 17.16, and the three-weeks RSI is set at 26.30 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 1.6498, while it was recorded at 0.8442 for the last single week of trading, and 2.4935 for the last 200 days.
Insight into Evofem Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -23234.08 and a Gross Margin at -269.73. Evofem Biosciences Inc.’s Net Margin is presently recorded at -31907.85.
Return on Total Capital for EVFM is now -200.98, given the latest momentum, and Return on Invested Capital for the company is -590.20. Return on Equity for this stock declined to -1,675.90, with Return on Assets sitting at -205.85. When it comes to the capital structure of this company, Evofem Biosciences Inc. [EVFM] has a Total Debt to Total Equity ratio set at 6,380.10. Additionally, EVFM Total Debt to Total Capital is recorded at 98.46, with Total Debt to Total Assets ending up at 78.15. Long-Term Debt to Equity for the company is recorded at 2,319.30, with the Long-Term Debt to Total Capital now at 35.79.
Reflecting on the efficiency of the workforce at the company, Evofem Biosciences Inc. [EVFM] managed to generate an average of -$968,088 per employee. Receivables Turnover for the company is 0.45 with a Total Asset Turnover recorded at a value of 0.01.Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.
EVFM Stock EPS
With the latest financial reports released by the company, Evofem Biosciences Inc. posted -0.91/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -145.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVFM.
Evofem Biosciences Inc. [EVFM] Insider Position Details
There are presently around $35 million, or 41.60% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: INVESCO LTD. with ownership of 9,293,989, which is approximately -26.815% of the company’s market cap and around 2.40% of the total institutional ownership; BLACKROCK INC., holding 5,607,803 shares of the stock with an approximate value of $4.63 million in EVFM stocks shares; and VANGUARD GROUP INC, currently with $3.44 million in EVFM stock with ownership of nearly 15.801% of the company’s market capitalization.
Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 64 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 13,880,140 shares. Additionally, 42 investors decreased positions by around 4,477,749 shares, while 21 investors held positions by with 24,341,875 shares. The mentioned changes placed institutional holdings at 42,699,764 shares, according to the latest SEC report filing. EVFM stock had 33 new institutional investments in for a total of 8,614,782 shares, while 19 institutional investors sold positions of 732,020 shares during the same period.